Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE2016, a First-in-Class Allogeneic Anti-EGFR Cell Therapy ...Middle East

ACE2016 Is an Allogeneic Gamma Delta 2 (γδ2) T Cell Therapy Targeting the Epidermal Growth Factor Receptor (EGFR) in Patients With Solid Tumors. Phase 1 Clinical Study Expected to Begin in H2 2024. ALAMEDA, Calif. and TAIPEI, Feb. 4, 2024 /PRNewswire/ -- Acepodia (6976:TT), a clinical...

Hence then, the article about acepodia announces fda clearance of investigational new drug application for ace2016 a first in class allogeneic anti egfr cell therapy was published today ( Monday 05/02/2024 - 03:16 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE2016, a First-in-Class Allogeneic Anti-EGFR Cell Therapy )

Also on site :

• Country Star Left Bleeding After Getting Struck in Face by Fan’s Phone
• ‘My mother was tricked by a fraudster pretending to be David Attenborough and gave them half of her life savings’
• Two weeks of war: Inside Trump’s risky decision to attack Iran — and the scramble to contain the fallout